Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein.

Bailey MJ, Broecker F, Freyn AW, Choi A, Brown JA, Fedorova N, Simon V, Lim JK, Evans MJ, García-Sastre A, Palese P, Tan GS.

J Virol. 2019 Jun 28;93(14). pii: e00405-19. doi: 10.1128/JVI.00405-19. Print 2019 Jul 15.

PMID:
31043537
2.

What viruses tell us about evolution and immunity: beyond Darwin?

Broecker F, Moelling K.

Ann N Y Acad Sci. 2019 Jul;1447(1):53-68. doi: 10.1111/nyas.14097. Epub 2019 Apr 29.

PMID:
31032941
3.

Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Sun W, Kirkpatrick E, Ermler M, Nachbagauer R, Broecker F, Krammer F, Palese P.

J Virol. 2019 May 29;93(12). pii: e00333-19. doi: 10.1128/JVI.00333-19. Print 2019 Jun 15.

PMID:
30944178
4.

Viruses and Evolution - Viruses First? A Personal Perspective.

Moelling K, Broecker F.

Front Microbiol. 2019 Mar 19;10:523. doi: 10.3389/fmicb.2019.00523. eCollection 2019.

5.

Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus.

Bailey MJ, Broecker F, Duehr J, Arumemi F, Krammer F, Palese P, Tan GS.

MBio. 2019 Apr 2;10(2). pii: e02861-18. doi: 10.1128/mBio.02861-18.

6.

Evolution of Immune Systems From Viruses and Transposable Elements.

Broecker F, Moelling K.

Front Microbiol. 2019 Jan 29;10:51. doi: 10.3389/fmicb.2019.00051. eCollection 2019. Review.

7.

A Wake-Up Call: We Need Phage Therapy Now.

Moelling K, Broecker F, Willy C.

Viruses. 2018 Dec 5;10(12). pii: E688. doi: 10.3390/v10120688. Review.

8.

Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model.

Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, Bermúdez González MC, Leyva-Grado VH, Evans MJ, Simon V, Lim JK, Krammer F, Hai R, Palese P, Tan GS.

Nat Commun. 2018 Nov 1;9(1):4560. doi: 10.1038/s41467-018-07008-0.

9.

Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans.

Sun W, Kang DS, Zheng A, Liu STH, Broecker F, Simon V, Krammer F, Palese P.

J Virol. 2019 Jan 4;93(2). pii: e01673-18. doi: 10.1128/JVI.01673-18. Print 2019 Jan 15.

10.

Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.

Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, Albrecht RA, Bouvier NM, Simon V, Nachbagauer R, Krammer F, Palese P.

J Clin Invest. 2018 Nov 1;128(11):4992-4996. doi: 10.1172/JCI122895. Epub 2018 Oct 8.

11.

Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Broecker F, Liu STH, Sun W, Krammer F, Simon V, Palese P.

J Virol. 2018 Sep 26;92(20). pii: e01100-18. doi: 10.1128/JVI.01100-18. Print 2018 Oct 15.

12.

Synthesis, Liposomal Formulation, and Immunological Evaluation of a Minimalistic Carbohydrate-α-GalCer Vaccine Candidate.

Broecker F, Götze S, Hudon J, Rathwell DCK, Pereira CL, Stallforth P, Anish C, Seeberger PH.

J Med Chem. 2018 Jun 14;61(11):4918-4927. doi: 10.1021/acs.jmedchem.8b00312. Epub 2018 May 18.

PMID:
29742893
13.

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Bailey MJ, Broecker F, Leon PE, Tan GS.

J Vis Exp. 2018 Feb 23;(132). doi: 10.3791/56256.

14.

RNase H As Gene Modifier, Driver of Evolution and Antiviral Defense.

Moelling K, Broecker F, Russo G, Sunagawa S.

Front Microbiol. 2017 Sep 14;8:1745. doi: 10.3389/fmicb.2017.01745. eCollection 2017. Review.

15.

Identification and Design of Synthetic B Cell Epitopes for Carbohydrate-Based Vaccines.

Broecker F, Seeberger PH.

Methods Enzymol. 2017;597:311-334. doi: 10.1016/bs.mie.2017.06.007. Epub 2017 Jul 22.

PMID:
28935109
16.

Fecal microbiota transplantation to fight Clostridium difficile infections and other intestinal diseases.

Moelling K, Broecker F.

Bacteriophage. 2016 Oct 21;6(4):e1251380. doi: 10.1080/21597081.2016.1251380. eCollection 2016.

17.

The intron-enriched HERV-K(HML-10) family suppresses apoptosis, an indicator of malignant transformation.

Broecker F, Horton R, Heinrich J, Franz A, Schweiger MR, Lehrach H, Moelling K.

Mob DNA. 2016 Dec 7;7:25. eCollection 2016.

18.

Stable core virome despite variable microbiome after fecal transfer.

Broecker F, Russo G, Klumpp J, Moelling K.

Gut Microbes. 2017 May 4;8(3):214-220. doi: 10.1080/19490976.2016.1265196. Epub 2016 Dec 9. Review.

19.

Synthetic Glycan Microarrays.

Broecker F, Seeberger PH.

Methods Mol Biol. 2017;1518:227-240.

PMID:
27873210
20.

Synthetic Lipoteichoic Acid Glycans Are Potential Vaccine Candidates to Protect from Clostridium difficile Infections.

Broecker F, Martin CE, Wegner E, Mattner J, Baek JY, Pereira CL, Anish C, Seeberger PH.

Cell Chem Biol. 2016 Aug 18;23(8):1014-1022. doi: 10.1016/j.chembiol.2016.07.009. Epub 2016 Aug 11.

21.

Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection.

Broecker F, Klumpp J, Moelling K.

Ann N Y Acad Sci. 2016 May;1372(1):29-41. doi: 10.1111/nyas.13100. Epub 2016 Jun 10.

PMID:
27286042
22.

Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation.

Broecker F, Klumpp J, Schuppler M, Russo G, Biedermann L, Hombach M, Rogler G, Moelling K.

Cold Spring Harb Mol Case Stud. 2016 Jan;2(1):a000448. doi: 10.1101/mcs.a000448.

23.

Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans.

Broecker F, Hanske J, Martin CE, Baek JY, Wahlbrink A, Wojcik F, Hartmann L, Rademacher C, Anish C, Seeberger PH.

Nat Commun. 2016 Apr 19;7:11224. doi: 10.1038/ncomms11224.

24.

Transcriptional signature induced by a metastasis-promoting c-Src mutant in a human breast cell line.

Broecker F, Hardt C, Herwig R, Timmermann B, Kerick M, Wunderlich A, Schweiger MR, Borsig L, Heikenwalder M, Lehrach H, Moelling K.

FEBS J. 2016 May;283(9):1669-88. doi: 10.1111/febs.13694. Epub 2016 Mar 25.

25.

Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites.

Möginger U, Resemann A, Martin CE, Parameswarappa S, Govindan S, Wamhoff EC, Broecker F, Suckau D, Pereira CL, Anish C, Seeberger PH, Kolarich D.

Sci Rep. 2016 Feb 4;6:20488. doi: 10.1038/srep20488.

26.

Generation of Monoclonal Antibodies against Defined Oligosaccharide Antigens.

Broecker F, Anish C, Seeberger PH.

Methods Mol Biol. 2015;1331:57-80. doi: 10.1007/978-1-4939-2874-3_5.

PMID:
26169735
27.

The reverse transcriptase-RNase H: from viruses to antiviral defense.

Moelling K, Broecker F.

Ann N Y Acad Sci. 2015 Apr;1341:126-35. doi: 10.1111/nyas.12668. Epub 2015 Feb 19. Review.

PMID:
25703292
28.

Epitope recognition of antibodies against a Yersinia pestis lipopolysaccharide trisaccharide component.

Broecker F, Aretz J, Yang Y, Hanske J, Guo X, Reinhardt A, Wahlbrink A, Rademacher C, Anish C, Seeberger PH.

ACS Chem Biol. 2014 Apr 18;9(4):867-73. doi: 10.1021/cb400925k. Epub 2014 Feb 6.

PMID:
24479563
29.

Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans.

Mietzsch M, Broecker F, Reinhardt A, Seeberger PH, Heilbronn R.

J Virol. 2014 Mar;88(5):2991-3003. doi: 10.1128/JVI.03371-13. Epub 2013 Dec 26.

30.

Analysis of the intestinal microbiome of a recovered Clostridium difficile patient after fecal transplantation.

Broecker F, Kube M, Klumpp J, Schuppler M, Biedermann L, Hecht J, Hombach M, Keller PM, Rogler G, Moelling K.

Digestion. 2013;88(4):243-51. doi: 10.1159/000355955. Epub 2013 Dec 5.

31.

The stoichiometry of peptide-heparan sulfate binding as a determinant of uptake efficiency of cell-penetrating peptides.

Wallbrecher R, Verdurmen WP, Schmidt S, Bovee-Geurts PH, Broecker F, Reinhardt A, van Kuppevelt TH, Seeberger PH, Brock R.

Cell Mol Life Sci. 2014 Jul;71(14):2717-29. doi: 10.1007/s00018-013-1517-8. Epub 2013 Nov 24.

PMID:
24270856
32.

RNase H: specificity, mechanisms of action, and antiviral target.

Moelling K, Broecker F, Kerrigan JE.

Methods Mol Biol. 2014;1087:71-84. doi: 10.1007/978-1-62703-670-2_7.

PMID:
24158815
33.

Generation and analysis of draft sequences of 'stolbur' phytoplasma from multiple displacement amplification templates.

Mitrović J, Siewert C, Duduk B, Hecht J, Mölling K, Broecker F, Beyerlein P, Büttner C, Bertaccini A, Kube M.

J Mol Microbiol Biotechnol. 2014;24(1):1-11. doi: 10.1159/000353904. Epub 2013 Oct 18.

PMID:
24158016
34.

Glycan arrays containing synthetic Clostridium difficile lipoteichoic acid oligomers as tools toward a carbohydrate vaccine.

Martin CE, Broecker F, Eller S, Oberli MA, Anish C, Pereira CL, Seeberger PH.

Chem Commun (Camb). 2013 Aug 18;49(64):7159-61. doi: 10.1039/c3cc43545h.

PMID:
23836132
35.

Immunological evaluation of a synthetic Clostridium difficile oligosaccharide conjugate vaccine candidate and identification of a minimal epitope.

Martin CE, Broecker F, Oberli MA, Komor J, Mattner J, Anish C, Seeberger PH.

J Am Chem Soc. 2013 Jul 3;135(26):9713-22. doi: 10.1021/ja401410y. Epub 2013 Jun 24.

PMID:
23795894
36.

Premature activation of the HIV RNase H drives the virus into suicide: a novel microbicide?

Broecker F, Andrae K, Moelling K.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1397-403. doi: 10.1089/aid.2012.0067. Epub 2012 Aug 29. Review.

PMID:
22931114
37.

Short hairpin-looped oligodeoxynucleotides reduce hepatitis C virus replication.

Broecker F, Moelling K.

Virol J. 2012 Jul 23;9:134. doi: 10.1186/1743-422X-9-134.

38.

The come-back clubs of Wisconsin.

BROECKER FH.

J Rehabil. 1951 Jul-Aug;17(4):18-9. No abstract available.

PMID:
14851336

Supplemental Content

Loading ...
Support Center